drugset / Trial / NCT05583617

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

NCT05583617

Phase 1/2 Recruiting 200 enrolled Hoffmann-La Roche
RandomizedSequentialOpen-labelTreatment

Summary

CO43923 is a platform study that will evaluate the safety, efficacy, and pharmacokinetics (PK) of multiple treatment combinations, as monotherapy or in combination, in participants with multiple myeloma (MM). The study is designed with the flexibility to open new treatment substudies as new treatments become available. Information regarding the opened substudies are found below.

Timeline

Start
2023-11-14
Primary completion
2028-07-31
Completion
2028-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cevostamab Monoclonal antibody Intravenous
Subject Iberdomide Small molecule Oral
Subject Lenalidomide Other / unclassified Oral
Background Dexamethasone Small molecule
Background Tocilizumab Monoclonal antibody

Indications